- Trials with a EudraCT protocol (205)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
205 result(s) found for: Drug court.
Displaying page 1 of 11.
EudraCT Number: 2015-001588-37 | Sponsor Protocol Number: ACHN-490-009 | Start Date*: 2015-07-15 | |||||||||||
Sponsor Name:Achaogen, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Multicenter, Double-Blind Study to Evaluate the Efficacy and Safety of Plazomicin Compared with Meropenem followed by Optional Oral Therapy for the Treatment of Complicated U... | |||||||||||||
Medical condition: Complicated Urinary Tract Infection (cUTI) Acute Pyelonephritis (AP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LV (Completed) CZ (Completed) BG (Completed) PL (Completed) ES (Completed) DE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001890-15 | Sponsor Protocol Number: SD-809-C-18 | Start Date*: 2014-11-12 |
Sponsor Name:Auspex Pharmaceuticals, Inc. | ||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA | ||
Medical condition: Tardive Dyskinesia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) PL (Completed) SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004740-36 | Sponsor Protocol Number: PTCEMF-GD-004 | Start Date*: 2019-10-14 | |||||||||||
Sponsor Name:PTC Therapeutics, Inc. | |||||||||||||
Full Title: A MULTICENTER RANDOMIZED PLACEBO-CONTROLLED PHASE 3 STUDY ON THE SAFETY AND EFFICACY OF DEFLAZACORT (EMFLAZA®) IN SUBJECTS WITH LIMB-GIRDLE MUSCULAR DYSTROPHY 2I (LGMD2I | |||||||||||||
Medical condition: Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001764-11 | Sponsor Protocol Number: PTC124-GD-030-DMD | Start Date*: 2020-01-21 | ||||||||||||||||
Sponsor Name:PTC Therapeutics, Inc. | ||||||||||||||||||
Full Title: A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ataluren (PTC124®) in Patients Aged ≥2 to <5 Years Old With Nonsense Mutation Dystrophinopathy | ||||||||||||||||||
Medical condition: nonsense mutation dystrophinopathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-005153-37 | Sponsor Protocol Number: LJ501-CRH04 | Start Date*: 2018-07-11 |
Sponsor Name:La Jolla Pharmaceutical Company | ||
Full Title: A Randomised, Placebo-controlled, Double-blind, Multicentre Efficacy and Safety Study of LJPC-501 in Paediatric Patients > 2 to 17 Years of Age with Catecholamine-Resistant Hypotension Associated w... | ||
Medical condition: Catecholamine-resistant hypotension associated with distributive shock | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: BE (Completed) EE (Completed) LT (Prematurely Ended) FR (Completed) ES (Temporarily Halted) GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000331-27 | Sponsor Protocol Number: ANB020-005 | Start Date*: 2018-09-18 | |||||||||||
Sponsor Name:AnaptysBio Inc | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profile of ANB020 Administered to Adult Subjects with Mode... | |||||||||||||
Medical condition: Moderate-to-Severe Atopic Dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002562-42 | Sponsor Protocol Number: TRCA-301E | Start Date*: 2017-12-15 | |||||||||||
Sponsor Name:Tricida, Inc. | |||||||||||||
Full Title: A Blinded, Placebo-Controlled Extension to Study TRCA-301 to Evaluate the Long-term Safety and Durability of Effect of TRC101 in Subjects with Chronic Kidney Disease and Metabolic Acidosis | |||||||||||||
Medical condition: Metabolic acidosis associated with Chronic Kidney Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) HU (Completed) SI (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000060-16 | Sponsor Protocol Number: AMIK-04-02 | Start Date*: 2005-05-06 |
Sponsor Name:Aerogen, Inc. | ||
Full Title: A Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Dose-Ranging Study of Nebulized Amikacin Delivered Via the Pulmonary Drug Delivery System (PDDS) in Patients With Ventilator-Associated Pn... | ||
Medical condition: Ventilator associated pneumonia (VAP) caused by gram negative organisms. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-002192-19 | Sponsor Protocol Number: ISIS678354-CS5 | Start Date*: 2022-07-22 | ||||||||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia | ||||||||||||||||||
Medical condition: Severe hypertryglyceridemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) HU (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) FI (Trial now transitioned) BG (Trial now transitioned) SK (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002939-15 | Sponsor Protocol Number: V56502 | Start Date*: 2017-01-24 | |||||||||||
Sponsor Name:VHsquared Ltd | |||||||||||||
Full Title: A Phase 2 study to investigate the efficacy, safety, and tolerability of six weeks treatment with V565 in subjects with active Crohn’s disease. | |||||||||||||
Medical condition: Active Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) AT (Completed) HU (Completed) SK (Completed) NL (Completed) NO (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003135-19 | Sponsor Protocol Number: SD-809-C-23 | Start Date*: 2015-02-06 |
Sponsor Name:Auspex Pharmaceuticals, Inc. | ||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE STUDY OF SD-809 (DEUTETRABENAZINE) FOR THE TREATMENT OF MODERATE TO SEVERE TARDIVE DYSKINESIA | ||
Medical condition: Tardive Dyskinesia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SK (Completed) PL (Completed) CZ (Completed) HU (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-002100-39 | Sponsor Protocol Number: PTC743-MIT-001-EP | Start Date*: 2021-07-26 | ||||||||||||||||
Sponsor Name:PTC THERAPEUTICS, INC. | ||||||||||||||||||
Full Title: Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy (MIT-E) | ||||||||||||||||||
Medical condition: Genetically determined mitochondrial disease and associated refractory epilepsy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Temporarily Halted) FR (Prematurely Ended) IT (Prematurely Ended) SE (Prematurely Ended) PL (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-001303-36 | Sponsor Protocol Number: TRCA-303 | Start Date*: 2018-11-07 | |||||||||||
Sponsor Name:Tricida Inc. | |||||||||||||
Full Title: A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects with Metabolic Acidosis | |||||||||||||
Medical condition: Chronic kidney disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BG (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Completed) SK (Completed) CZ (Completed) BE (Completed) ES (Prematurely Ended) PT (Completed) NL (Prematurely Ended) PL (Completed) IT (Prematurely Ended) RO (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005019-16 | Sponsor Protocol Number: ROCKSAN | Start Date*: 2009-03-19 |
Sponsor Name:AMC- academisch psychiatrisch centrum | ||
Full Title: Randomized Olanzapine Clozapine Key study on Schizophrenia and Addiction in the Netherlands (ROCKSAN) | ||
Medical condition: A multi-centre prospective, randomized, double blind designed study examining the effectiveness and costs of clozapine compared to olanzapine in patients with schizophrenia or related psychotic dis... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-000360-42 | Sponsor Protocol Number: UX001-CL302 | Start Date*: 2016-08-02 | ||||||||||||||||
Sponsor Name:Ultragenyx Pharmaceutical Inc. | ||||||||||||||||||
Full Title: A Phase 3b Open-label Extension Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients with GNE Myopathy (GNEM) or Hereditary Inclusion Body Myo... | ||||||||||||||||||
Medical condition: GNE Myopathy, also known as Hereditary Inclusion Body Myopathy (HIBM), Distal Myopathy with Rimmed Vacuoles (DMRV), Nonaka's disease, or quadriceps sparing myopathy (QSM) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) BG (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001875-32 | Sponsor Protocol Number: UX003-CL202 | Start Date*: 2015-11-12 |
Sponsor Name:Ultragenyx Pharmaceutical Inc. | ||
Full Title: A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects with MPS 7 | ||
Medical condition: Mucopolysaccharidosis type 7 (MPS 7, Sly syndrome) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA PT (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-000389-69 | Sponsor Protocol Number: UX007G-CL202 | Start Date*: 2017-01-27 | |||||||||||
Sponsor Name:Ultragenyx Pharmaceutical Inc | |||||||||||||
Full Title: An Open-label Extension Study to Assess the Long-term Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome | |||||||||||||
Medical condition: Glucose Transporter Type 1 deficiency syndrome | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002165-21 | Sponsor Protocol Number: ISIS416858-CS5 | Start Date*: 2017-11-23 | ||||||||||||||||
Sponsor Name:Ionis Pharmaceuticals Inc. | ||||||||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ISIS 416858 (IONIS-FXIRX an Antisense Inhibitor of Factor XI... | ||||||||||||||||||
Medical condition: Prevention of thrombosis while on hemodialysis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) CZ (Completed) AT (Completed) NL (Completed) BG (Completed) BE (Completed) GR (Completed) LV (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-005115-13 | Sponsor Protocol Number: ISIS420915-CS4 | Start Date*: 2018-04-25 | |||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Non-Interventional Study to Monitor the Survival Status of Patients that Discontinued from ISIS 420915-CS2 or ISIS 420915-CS3 | |||||||||||||
Medical condition: Familial Amyloid Polyneuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Ongoing) GB (Completed) PT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000489-37 | Sponsor Protocol Number: SURF-04-01 | Start Date*: 2005-08-26 |
Sponsor Name:Nektar Therapeutics | ||
Full Title: An open label, randomized, controlled study to evaluate the safety and efficacy of aerosolized surfactant, Curosurf®, delivered via nasal continuous positive airway pressure pulmonary drug delivery... | ||
Medical condition: The medical condition for this application is the Respiratory Distress Syndrome (RDS). RDS, also known as hyaline membrane disease, is characterized by lung immaturity and surfactant deficiency a... | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
